Pilot Trial of pTVG-HP DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
Phase of Trial: Phase I/II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs MVI 816 (Primary) ; Pembrolizumab (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Aug 2017 According to Madison Vaccines media release, first patient has been dosed in an expanded cohort of 20 patients with metastatic, castrate-resistant prostate cancer, who will be offered the combination regimen for up to 48 weeks
- 27 Jun 2017 Planned End Date changed from 1 Sep 2019 to 1 Apr 2019.
- 27 Jun 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Apr 2018.